Imidazo-, pyrazolopyrazines and imidazotriazines and their use
View Patent ↗The invention relates to substituted imidazo-, pyrazolopyrazines and imidazotriazines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of hematological disorders, preferably of leukopenias and neutropenias.
1. A compound of the formula
in which
U represents CH,
represents CR 12 ,
W represents N,
A represents CR 15 ,
where
R 12 represents hydroxycarbonyl, C 1 -C 4 -alkoxycarbonyl, or —CH 2 R 13 ,
and
where
R 13 represents morpholinyl,
R 15 represents hydrogen,
R 1 represents a group of the formula
where
* is the point of attachment to the heterocycle, and
R 3 represents 2-pyridyl, 1,3-thiazol-2-yl, 1,3-thiazol-4-yl, or 1H-1,2,4-triazol-5-yl,
where 2-pyridyl, 1,3-thiazol-2-yl and 1,3-thiazol-4-yl are substituted by 1 or 2 substituents, where the substituents independently of one another are selected from the group consisting of halogen, cyano, nitro, amino, trifluoromethyl, trifluoromethoxy, aminocarbonyl, trifluoromethylcarbonyl, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino, C 3 -C 4 -cycloalkylamino, C 1 -C 4 -alkylcarbonyl, C 1 -C 4 -alkoxycarbonyl, C 1 -C 4 -alkylaminocarbonyl and C 3 -C 6 -cycloalkylcarbonyl,
where alkyl, alkoxy, alkylamino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl and cycloalkylcarbonyl may be substituted by a substituent, where the substituent is selected from the group consisting of halogen, cyano, hydroxyl, amino, trifluoromethyl and C 3 -C 6 -cycloalkyl,
and
where 1H-1,2,4-triazol-5-yl, may be substituted by a substituent, where the substituent is selected from the group consisting of halogen, cyano, nitro, amino, trifluoromethyl, trifluoromethoxy, aminocarbonyl, trifluoromethylcarbonyl, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino, C 3 -C 4 -cycloalkylamino, C 1 -C 4 -alkoxycarbonyl, C 1 -C 4 -alkylaminocarbonyl and C 3 -C 6 -cycloalkylcarbonyl,
R 2 represents phenyl,
where phenyl may be substituted by 1 to 3 halogen substituents,
or one of its salts.
2. The compound as claimed in claim 1 , characterized in that R 2 is phenyl optionally substituted by 1 to 2 halogen substituents.
3. A pharmaceutical composition, comprising a compound as claimed in claim 1 in combination with an inert non-toxic pharmaceutically acceptable auxiliary.